Biocon Share Price

Biocon Limited started in Bengaluru back in 1978 as a joint venture between an Irish company, Biocon Biochemicals Limited, and Kiran Mazumdar-Shaw. At first, they were mainly exporting enzymes to the US and Europe. It didn’t take long for them to branch out and soon they moved into biologics, insulin products, and contract research. Now, Biocon isn’t just a local player. It began operations by exporting enzymes to the US and Europe and later expanded into biologics, insulin products, and contract research services. Over the years, Biocon has built a global presence across the US, Europe, Latin America, and emerging markets.

The company is listed on both the Bombay Stock Exchange (BOM: 532523) and the National Stock Exchange (NSE: BIOCON).

Biocon Business Segments And Revenue Model

Biocon operates through a diversified biopharmaceutical model spanning biosimilars, generic formulations, APIs, and contract research services. The biosimilars business remains the company’s major growth driver, supported by products in oncology, diabetes, and immunology across advanced and emerging markets.

The company’s generic formulations segment focuses on developing a portfolio of complex generic formulations. Biocon also generates revenue from its API business through fermentation-based and synthetic active pharmaceutical ingredients used in chronic therapies.

Its research services arm, Syngene International, provides research, development and manufacturing services to global pharmaceutical and biotech companies through long-term contracts and dedicated research centres. Biocon’s overall revenue model is driven by product sales, licensing income, strategic partnerships, and contract research revenues.

Biocon Key Milestones

• 1978: The company was set up as a joint venture.
  
• 2001: Became the first company globally to get approval from the U.S. Food and Drug Administration (FDA) to make Lovastatin API.
  
• 2004: Went public.
  
• 2006: Inaugurated Biocon Park in Bengaluru.
  
• 2009: Tied up with Mylan for developing biosimilars.
  
• 2015: Syngene debuted on the Indian stock market.
  
• 2018: Partnered with Sandoz for global markets.
  
• 2020: Itolizumab got DCGI nod for restricted emergency use in India.
  
• 2023: Biocon Biologics launched HULIO® in the US.
  
• 2025: Launched gLiraglutide for diabetes and obesity in the UK.
  

Biocon ESG And Sustainability

• EHS management systems conforming to ISO 14001:2015 and ISO 45001:2018 standards have been implemented in all plants.
  
• A zero liquid discharge system has been implemented at manufacturing units to purify and recycle wastewater.
  
• The company has reduced CO2 emissions by using PNG (Piped Natural Gas) for steam generation.
  
• 53% of total power requirement is sourced from renewable energy sources.
  
• The company has installed a two-stage scrubber system at multiple-effect evaporator systems to ensure better air quality in and around its facilities.
  
• Biocon Foundation, in collaboration with the Bengaluru Science and Technology Cluster (BeST Cluster) and the National Centre for Biological Sciences (NCBS), provides women internships to help them build careers in STEM.
  

Biocon Awards And Recognitions

• Shreehas Tambe was recognised as one of the Most Promising Business Leaders of Asia, 2026.
  
• Kiran Mazumdar-Shaw was honoured with the prestigious Honorary Fellowship of the Academy of Medical Sciences (UK) in 2026 in recognition of her remarkable contributions to the advancement of healthcare, biomedical sciences, and global access to affordable medicines.
  
• Won the Bioprocessing Excellence in South Asia Award at the Asia Pacific Biopharma Excellence Awards (ABEA) 2025.
  
• Received National EHS Award in the Large Enterprises - Pharmaceuticals Sector at the prestigious 12th Global Safety Summit, 2025.